BUSINESSAug 3 · 07:08 UTCTHE GUARDIAN WORLDJulia Kollewe

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

AstraZeneca is in talks to acquire Bristol Myers Squibb in a potential $400bn merger, creating the world’s fourth-largest drugmaker. AstraZeneca, the UK’s second-biggest listed company, has a market value of nearly £196bn, while BMS, based in Princeton, is valued at $133bn.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

AstraZenecaorganizationBristol Myers SquibborganizationPascal SoriotpersonPrincetonplacepharmaceutical mergertopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSAug 3 · 07:08 UTC
AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
BUSINESSAug 2 · 20:12 UTC
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
BUSINESSAug 2 · 21:27 UTC
AstraZeneca said to have explored Bristol Myers merger
BUSINESSAug 2 · 20:13 UTC
AstraZeneca Said to Have Explored Bristol Myers Merger
BUSINESSAug 2 · 21:40 UTC
AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
BUSINESSAug 3 · 05:46 UTC
AstraZeneca Is Said to Have Explored Bristol Myers Merger